STAT

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle lossWorldPing

A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

More coverage: all health news on WorldPing.

Related news